Abstract
In the area of lead optimization for potential CNS-active drugs in medicinal chemistry, there is a great need for experimental methodologies that can generate data relevant to estimates of free (unbound) drug exposure within the CNS. The methods chosen have to be efficient and have to measure a pharmacologically relevant entity. The lack of methods for generating such data is probably linked with the lack of successful lead optimization strategies within CNS drug discovery. This article evaluates available methods for estimating drug delivery to the brain, and discusses the relevance of the methods from the perspective of CNS exposure to free drug. It is suggested that the extent of drug delivery is the most important investigative parameter, since permeability (rate of transfer) can vary within a relatively wide range and still allow effects within the CNS. Following this suggestion would shift the focus from the current way of thinking and could lead to the development of less lipophilic compounds than are currently being investigated. It is concluded that an extensive collection of quality data on brain drug delivery, transporter affinities and in vivo behavior is urgently required so as to be able to build relevant predictive in vitro and in silico models for the future. These models need to be much more focused on the asymmetry of active transport across the BBB than on permeability data.
Current Topics in Medicinal Chemistry
Title: Methodologies to Assess Brain Drug Delivery in Lead Optimization
Volume: 9 Issue: 2
Author(s): Margareta Hammarlund-Udenaes, Ulf Bredberg and Markus Friden
Affiliation:
Abstract: In the area of lead optimization for potential CNS-active drugs in medicinal chemistry, there is a great need for experimental methodologies that can generate data relevant to estimates of free (unbound) drug exposure within the CNS. The methods chosen have to be efficient and have to measure a pharmacologically relevant entity. The lack of methods for generating such data is probably linked with the lack of successful lead optimization strategies within CNS drug discovery. This article evaluates available methods for estimating drug delivery to the brain, and discusses the relevance of the methods from the perspective of CNS exposure to free drug. It is suggested that the extent of drug delivery is the most important investigative parameter, since permeability (rate of transfer) can vary within a relatively wide range and still allow effects within the CNS. Following this suggestion would shift the focus from the current way of thinking and could lead to the development of less lipophilic compounds than are currently being investigated. It is concluded that an extensive collection of quality data on brain drug delivery, transporter affinities and in vivo behavior is urgently required so as to be able to build relevant predictive in vitro and in silico models for the future. These models need to be much more focused on the asymmetry of active transport across the BBB than on permeability data.
Export Options
About this article
Cite this article as:
Hammarlund-Udenaes Margareta, Bredberg Ulf and Friden Markus, Methodologies to Assess Brain Drug Delivery in Lead Optimization, Current Topics in Medicinal Chemistry 2009; 9 (2) . https://dx.doi.org/10.2174/156802609787521607
DOI https://dx.doi.org/10.2174/156802609787521607 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oestradiol Signalling in the Hippocampus
Current Neuropharmacology Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance
Current Pharmaceutical Design Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy The Rise of Carbapenem-Resistant Acinetobacter baumannii
Current Pharmaceutical Design Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Treating Schizophrenia: Novel Targets for the Cholinergic System
CNS & Neurological Disorders - Drug Targets Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Neurological Disorders in Pregnancy
Current Women`s Health Reviews Newer Cephalosporins are Only Marginal Advancements Over Existing Compounds
Current Medicinal Chemistry - Anti-Infective Agents Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Update on the Development of TB Vaccines
Current Pharmaceutical Biotechnology